Literature DB >> 31003622

Change in albuminuria as a surrogate endpoint in chronic kidney disease - Authors' reply.

Hiddo J L Heerspink1, Josef Coresh2, Ron T Gansevoort3, Lesley A Inker4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 31003622     DOI： 10.1016/S2213-8587(19)30080-4

Source DB:  PubMed          Journal:  Lancet Diabetes Endocrinol        ISSN： 2213-8587            Impact factor:   32.069


× No keyword cloud information.
  4 in total

Review 1.  The New Biology of Diabetic Kidney Disease-Mechanisms and Therapeutic Implications.

Authors:  Yuliya Lytvyn; Petter Bjornstad; Daniel H van Raalte; Hiddo L Heerspink; David Z I Cherney
Journal:  Endocr Rev       Date:  2020-04-01       Impact factor: 19.871

2.  Early Change in Albuminuria with Canagliflozin Predicts Kidney and Cardiovascular Outcomes: A Post Hoc Analysis from the CREDENCE Trial.

Authors:  Megumi Oshima; Brendon L Neuen; JingWei Li; Vlado Perkovic; David M Charytan; Dick de Zeeuw; Robert Edwards; Tom Greene; Adeera Levin; Kenneth W Mahaffey; Luca De Nicola; Carol Pollock; Norman Rosenthal; David C Wheeler; Meg J Jardine; Hiddo J L Heerspink
Journal:  J Am Soc Nephrol       Date:  2020-09-30       Impact factor: 10.121

3.  Exenatide once weekly decreases urinary albumin excretion in patients with type 2 diabetes and elevated albuminuria: Pooled analysis of randomized active controlled clinical trials.

Authors:  Annemarie B van der Aart-van der Beek; Daniel H van Raalte; Cristian Guja; Klaas Hoogenberg; Lisa J Suchower; Elise Hardy; C David Sjöström; Hiddo J L Heerspink
Journal:  Diabetes Obes Metab       Date:  2020-05-29       Impact factor: 6.577

Review 4.  Mitochondria in Diabetic Kidney Disease.

Authors:  Amna Ayesha Ahmad; Shayna Odeal Draves; Mariana Rosca
Journal:  Cells       Date:  2021-10-29       Impact factor: 6.600
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.